David Krasnostein joined the Board on 11 March 2021 and was appointed Chairman on 25 May 2021.

David brings extensive legal and business experience across a distinguished corporate career and board representation.

Formerly General Counsel and Group Director, Strategic Planning and Development at Telstra; Group Chief General Counsel at National Australia Bank; and Chief Executive Officer of MLC Private Equity (one of Australia’s oldest and largest private equity firms with over $3 billion invested globally during his tenure), David practised law in the USA at the Wall St firm of Sullivan & Cromwell and as a partner of the Chicago law firm, Sidley Austin.

David has held directorships with the Transport Accident Commission and was Chairman of the Victorian Work Cover Authority from 2015-2018. He is a past Chairman and director of the advisory board of Qualitas Pty Ltd and Arch Finance Pty Ltd, one of Australia’s leading non-bank property lenders. He is also on the board for the National Breast Cancer foundation, The Hellenic Museum of Victoria, and The Aikenhead Centre For Medical Discovery.

Lachlan McKinnon was appointed Chief Executive Officer in January 2020 and Managing Director in May 2020.

Lachlan has significant international sales and marketing experience at a senior level. Prior to joining Phoslock, he held various management roles with Nufarm Limited (ASX: NUF) in Australia, Europe and North America over almost 30 years, most recently as country manager for Canada and head of business development for the Americas. Nufarm is a leading global agricultural chemicals business (FY2018/19 Sales $3.8 billion) with manufacturing and marketing operations across five continents.

He holds a Bachelor of Agricultural Science from La Trobe University, Melbourne; a Graduate Diploma of Business (Agribusiness) from Monash University Melbourne; a Master of Enterprise, School of Enterprise, Melbourne University; and the Harvard Business School Short Course – Agribusiness.

Bob Prosser joined the Board on 11 March 2021 and chairs the Company’s Audit and Risk Committee.

Bob has extensive experience as a director and is a chartered accountant and former partner at PricewaterhouseCoopers (PwC). During his career at PwC, he gained expertise in accounting, audit, transactions, tax, valuation, structuring, commercial legal issues, corporate governance, compliance, strategy and risk across organisations of all sizes and in many industry sectors.

Bob has held directorships with ASX listed companies including Australand Property Group and is currently chair of the Audit, Risk and Investment committee of the National Breast Cancer Foundation.

Barry Sechos joined the Board on 1 February 2021.

Barry has over 30 years' experience as a director, business executive and corporate lawyer. He commenced his career as a commercial lawyer at the law firm Allen Allen & Hemsley, specialising in banking and finance law, working in Australian, Singapore and London offices. He has strong experience and understanding of international business environments and capital markets.

Director of the Sherman Group Pty Limited, a Sydney-based privately owned investment company, Barry is also a director and principal of Paddington St Finance Pty Limited, a specialist structured finance company providing R&D tax incentive finance and mid-market corporate loans to emerging corporations domiciled in Australia, and Fulcrum Media Finance Pty Ltd, a finance company providing Producer Offset Finance to Australian and New Zealand film production companies. His other directorships include See-Saw Films, Transmission Films, Regeneus Limited, and Concentrated Leaders Fund Limited.

Brenda Shanahan joined the Board on 15 September 2017.

Brenda is a graduate of Melbourne University in Economics and Commerce and a Fellow of the Institute of Directors. With a finance research background in Australian and overseas economies and share markets, she has held a number of executive positions including as Managing Director and a member of the international board of WM Mercer Investment Consulting for Australia and Asia.

Brenda is a former director of Equitilink Limited and of ASX-listed Challenger Financial Services as an independent non-executive director of Challenger Limited, where she was a member of the group Risk Committee, Group Audit Committee, Remuneration Committee and Nomination Committee.

Her other directorships include Bell Financial Group Limited, Clinuvel Pharmaceuticals Limited, DMP Asset Management Limited, St Vincent's Medical Research Institute in Melbourne Foundation, and as Chair of the Aitkenhead Centre for Medical Discovery. Brenda was recently bestowed with an honorary Doctorate from Swinburne University of Technology.

Matthew Parker was appointed as Chief Financial Officer and Company Secretary in May 2020.

Matthew has extensive experience in all aspects of international financial management, control, planning and analysis, including with ASX listed companies Gale Pacific (ASX:GAP; global marketing and manufacturing) and Paragon Care (ASX:PGC; healthcare).

Prior to joining Phoslock, he was Group CFO for Private Equity owned (Marlin Brands) where he led significant programs in financial restructuring, debt raising and general governance management. He has also held key international finance roles at Ford Motor Company and Cadbury Schweppes.

A Certified Practising Accountant, Matthew holds a Bachelor of Business Administration (Accounting and Finance) and a Bachelor of Arts (Japanese) from Swinburne University of Technology. He is a registered member of CPA Australia and an affiliate of the Securities Institute of Australia.